Michelle W. | Leland

Michelle W.

HBS Grad in VC - for startup or non-traditional backgrounds

Studied at University of Chicago

Works at Wavemaker 360

Available tomorrow at 11:30 PM UTC

Protected by the Leland Experience Guarantee

Available tomorrow at 11:30 PM UTC

Questions? Start chatting with this coach before you get started.

Michelle's Coaching Offerings

Craft Powerful MBA Essays

Craft winning MBA essays through brainstorming, drafting, and editing

Starting at $3605h+ of coaching

Comprehensive MBA Application Package — Land Your Dream Program

Expert help on your MBA essays, recommendations, resume, and more

Starting at $2,20020h+ of coaching

Nail the MBA Interview

Practice realistic mock MBA interviews with a trained expert

Starting at $2253h+ of coaching

Custom hourly

Get help with Editing, Recommendations, and .

Michelle’s MBA Qualifications

I recently completed by MBA at Harvard Business School. I started my career in banking, and spent a few years prior to school at growth stage startups doing finance, strategy, and operations. During business school, I explored and worked with early stage startups, and now I work as an early stage health tech investor. Whether you need guidance on application strategy, essay writing, or interview preparation, I'm here to support you every step of the way.

Michelle can help with:

Editing

Recommendations

Interviews

School Selection

Secondary Review

Application Strategy

Essays

Resume

Michelle also coaches for Venture Capital and Career Coaching. View all.

Work Experience

Health Tech Investor

Wavemaker 360

January 2025 - Present

Wavemaker Three-Sixty Health is the leading U.S. early stage (Seed and Series A) venture capital fund focused 100% on healthcare. We're backed by healthcare LPs - both leading organizations and healthcare professionals - across providers (throughout the continuum of care), payers and pharma. This gives us a unique advantage when it comes to discovering compelling healthcare startups, evaluating their business models and investability, and most importantly, commercially supporting these early-stage health-tech companies. We invest in healthcare IT, digital health, medical device, pharma-tech, AI and science - we do not invest in bio-pharma. Currently deploying capital out of Fund III.